-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On May 26, Guangdong Dongyang Sunshine Technology Holdings Co.
Rivaroxaban is an anticoagulant drug used in adult patients with elective hip or knee replacement surgery to prevent venous thrombosis (VTE); or to treat adult venous thrombosis (DVT) to reduce the recurrence of DVT after acute DVT And the risk of pulmonary embolism (PE); or for those with one or more risk factors (for example: congestive heart failure, hypertension, age ≥75 years, diabetes, stroke or transient ischemic attack history) Adult patients with valvular atrial fibrillation to reduce the risk of stroke and systemic embolism.
Rivaroxaban is a category B product in the 2020 edition of the National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog, and it is also a category in the 2018 edition of the National Essential Drug List.
The product is Rivaroxaban tablets, one of 27 generic drugs purchased by the company's holding subsidiary, Yichang Dongguang Yangtze Pharmaceutical Co.